Prilosec Long-Term Efficacy Acknowledged By FDA Advisory Committees
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca/Procter & Gamble's decision to seek a 20 mg OTC dose for Prilosec was endorsed by FDA advisory committee members at a meeting in Gaithers-burg, Md Oct. 20.
You may also be interested in...
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Eighty-one percent of 866 participants in the Prilosec 1 actual use study correctly chose the heartburn medication as appropriate for them to use, Procter & Gamble OTC Drug Development Director Douglas Bierer, PhD, reported (See chart: "1The Prilosec 1 NDA: Take 2")
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Eighty-one percent of 866 participants in the Prilosec 1 actual use study correctly chose the heartburn medication as appropriate for them to use, Procter & Gamble OTC Drug Development Director Douglas Bierer, PhD, reported (See chart: "1The Prilosec 1 NDA: Take 2")
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Eighty-one percent of 866 participants in the Prilosec 1 actual use study correctly chose the heartburn medication as appropriate for them to use, Procter & Gamble OTC Drug Development Director Douglas Bierer, PhD, reported (See chart: "1The Prilosec 1 NDA: Take 2")